TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fibromyalgia Impact Questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response interference on the Stroop Color and Word Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color naming abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word naming speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of anxiety or adjustment disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily∑ TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increases in alanine transaminase and aspartate transaminase values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Potency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of IL-2 positive CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of IFN-gamma positive CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of IL-4/IFN-gamma positive CD4+ and CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breakup Time (BR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Tear Breakup Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Central Corneal Thickness (CCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean fracture strengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean muTBSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serum glucose disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalization of Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical progression-free survival (CPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Skeletal-related event (SRE)-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Mean total energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of corneal ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retinal changes identified with SD‐OCT or FAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative anxiety ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total aggregate block score (sensory+motor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Ambulation (TTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in red blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean TSH, FT4, and FT3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hypertensive disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Small for gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: acute glucose-stimulated insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sedentary behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of gastric and pancreatic lipases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recurrence of open NTD
Endpoint domain: Mortality/survival
Primary endpoint: Breathlessness Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Vital Capacity (FVC%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decayed, missing, and filled teeth (DMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache scores after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to normal levels of cancer antigen-125
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proximal femur BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DIAGNOdent Pen scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICDAS II scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to accurately compare nutrition information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean glucose (0-10 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental adjusted weighted mean glucose (0-4 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vestibular ratio scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance (quiet stance BoS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute phase inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hirsutism score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual dysfunction frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding rates at 6 months postpartum
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of stopping exclusively breastfeeding
Endpoint domain: Mortality/survival
Primary endpoint: Treatment-related deaths
Endpoint domain: Adverse events/effects
Primary endpoint: appropriate assessment and overall care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of predicted PEFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urge-to-cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feed intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bother from urinary incontinence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reactions to rofecoxib
Endpoint domain: Adverse events/effects
Primary endpoint: Need for MROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measured blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyclops lesions formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extension loss (cyclops syndrome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-sectional area of the femoral intercondylar notch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior cingulate activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IBS of the segment of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVIB of the segment of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success rates based on global responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ARS proportion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ANS proportion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amoxicillin resistance (mean MIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peptide YY area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucagon-like peptide-1 AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual analog scale fullness ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative chest drain bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lysholm Score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical component summary of life quality (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to first relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sinus pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of warts without scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scintigraphic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: INA class status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIQLI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: red blood cells transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for strain to pass a motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: craving and withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall per-patient yearly costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak enhancement value of the pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak divergence velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean EQ-VAS change from BOP to week 9 of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enrollment of participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bone mineral density (BMD) of the lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overprescription of antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overprescription of antiulcerative agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmaceutical expenditure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Aneurysm size assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time required to estimate AOP and set the tourniquet cuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial tourniquet pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tourniquet pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in hearing‐related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Barrett's oesophagus segment length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum gastrin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vomiting frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Rectosigmoid aphthous ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: gamma50 for dose-tumour control relation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha/beta values for late normal tissue damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of non-hypoxaemic apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of manual reventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean increase in steps/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: relief of congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak exercise oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aortic distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VAS score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active and passive ROM changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of hypovolaemia-related haemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of normal TBV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median household costs associated with uncomplicated malaria
Endpoint domain: Resource use
Endpoint subdomain: Household
Primary endpoint: Median health system costs associated with malaria
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall cost of malaria care to society
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: set-shifting ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: semantic language fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow extension range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arm trajectory smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hunger scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Receipt of HMG‐CoA reductase inhibitors, beta‐adrenergic blocking agents, and ACE inhibitors
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median duration of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with blood pressure below goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alleviation of hypoproteinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lake Louise Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor unit conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor unit discharge rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biceps femoris‐vasti coactivation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor neurologic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 3-month mRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for additional antiemetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Occurrence of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of dactylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: client outcome improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: client-rated alliance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative shoulder pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete angiographic occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month event rate
Endpoint domain: Mortality/survival
Primary endpoint: standardized resource-based relative-value units (RBRVUs)
Endpoint domain: Resource use
Primary endpoint: plasma TC concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TC:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in non-verbal active listening skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Calendar of Premenstrual Experiences scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Profile of Mood States subscales scores (depression, tension, anger)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete histologic response (>90% decrease in mean eosinophil count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in Larsen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with no erosive changes in large joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with care during the postpartum period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in inflammatory biomarkers (C-reactive protein and interleukin-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EPC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: end-stage lung disease development
Endpoint domain: Mortality/survival
Primary endpoint: GAF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative pulmonary function test values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Atelectasis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in Q-LES-Q SF scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of silica gel in treating recurrent herpes labialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of silica gel compared to acyclovir cream
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in the angle of passive ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in the MAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in the GOS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of dose adjustments
Endpoint domain: Adverse events/effects
Primary endpoint: Retention until randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time from first puncture to guidewire insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinician performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge in newborn care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confidence in newborn care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Remission at week 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 acute toxicity incidence
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year BDSF
Endpoint domain: Mortality/survival
Primary endpoint: Progression of nephropathy stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Avoidance of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: total function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal triceps skinfold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Eyecor Camera system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Eyecor Camera system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of Eyecor Camera system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic balance assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unsuspected malignancy rate
Endpoint domain: Adverse events/effects
Primary endpoint: 13C-UBT data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of steatosis on baseline biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes